Moat Ross
SEC CIK 1857177 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals International, plc | Chief Commercial Off | 20.3K | — | $5.83M | 50 | 2021-07-15 | 2026-09-01 |
Most active insiders at KNSA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Patel Sanj K | COB, CEO, Dir | — | $39.43M |
| 2 | Paolini John F. | Chief MEDICAL Off | — | $8.00M |
| 3 | Ragosa Mark | CFO | — | $5.56M |
| 4 | Tessari Eben | Chief STRATEGY Off | — | $3.10M |
| 5 | Quart Barry D | Dir | — | $2.68M |
| 6 | Megna Michael R | CAO | — | $2.64M |
| 7 | Cole G Bradley | Dir | — | $299.1K |
| 8 | Moat Ross | COO | — | $194.5K |
| 9 | McCain Tracey L | Dir | — | — |
| 10 | Levy Richard S | Dir | — | — |
Transactions 50
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-09-03 16:41 | 2026-09-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | M - OptEx | — | +8,285 | 20.3K | +69% | — |
| D | 2026-09-03 16:41 | 2026-09-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | F - Tax | $79.28 | -4,007 | 16.3K | -20% | -$317.7K |
| T | 2026-04-13 16:34 | 2026-04-09 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | S - Sale | $46.69 | -1,703 | 12.0K | -12% | -$79.5K |
| DT | 2026-04-08 16:39 | 2026-04-06 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | S - Sale+OE | $48.58 | -2,367 | 12.0K | -16% | -$115.0K |
| DT | 2026-04-08 16:39 | 2026-04-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | M - OptEx | — | +2,477 | 14.5K | +21% | — |
| DT | 2026-04-08 16:39 | 2026-04-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | F - Tax | $48.94 | -774 | 13.7K | -5% | -$37.9K |
| D | 2026-04-03 16:35 | 2026-01-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | A - Grant | $24.16 | +879 | 10.3K | +9% | +$21.2K |
| D | 2026-04-03 16:35 | 2026-04-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | M - OptEx | — | +5,808 | 16.1K | +56% | — |
| D | 2026-04-03 16:35 | 2026-04-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | COO | F - Tax | $48.13 | -1,706 | 14.4K | -11% | -$82.1K |
| 2025-09-08 | 2025-09-04 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | CHIEF CORP, COMM. Off | S - Sale | $35.31 | -3,523 | 9,415 | -27% | -$124.4K | |
| DM | 2025-09-03 | 2025-09-01+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | CHIEF CORP, COMM. Off | M - OptEx | — | +6,823 | 11.2K | +157% | — |
| DM | 2025-09-03 | 2025-09-01+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | CHIEF CORP, COMM. Off | F - Tax | $33.61 | -3,300 | 12.4K | -21% | -$110.9K |
| D | 2025-06-05 | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | S - Sale+OE | $29.02 | -27.6K | 9,415 | -75% | -$800.8K |
| D | 2025-06-05 | 2025-06-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $13.35 | +27.6K | 37.0K | +293% | +$368.4K |
| DM | 2025-05-05 | 2025-05-02+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $17.76 | +10.1K | 15.7K | +182% | +$179.8K |
| DM | 2025-05-05 | 2025-05-02+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | S - Sale+OE | $28.00 | -10.1K | 9,415 | -52% | -$283.4K |
| DM | 2025-05-01 | 2025-04-29+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $13.45 | +87.3K | 73.5K | New | +$1.17M |
| DM | 2025-05-01 | 2025-04-29+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | S - Sale+OE | $25.96 | -87.3K | 9,415 | -90% | -$2.27M |
| 2025-04-23 | 2025-04-21 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | S - Sale | $20.29 | -18.3K | 9,415 | -66% | -$370.5K | |
| D | 2025-04-09 | 2025-04-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +2,477 | 28.4K | +10% | — |
| D | 2025-04-09 | 2025-04-07 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $20.28 | -727 | 27.7K | -3% | -$14.7K |
| DM | 2025-04-03 | 2025-04-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $21.77 | -984 | 26.4K | -4% | -$21.4K |
| DM | 2025-04-03 | 2025-04-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +3,352 | 25.2K | +15% | — |
| D | 2025-03-19 | 2025-01-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | A - Grant | $16.00 | +1,118 | 22.9K | +5% | +$17.9K |
| D | 2025-03-19 | 2025-03-16 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $22.61 | -292 | 23.6K | -1% | -$6,602 |
| D | 2025-03-19 | 2025-03-16 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +994 | 23.8K | +4% | — |
| D | 2024-09-04 | 2024-07-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | A - Grant | $15.65 | +211 | 18.4K | +1% | +$3,302 |
| DM | 2024-09-04 | 2024-09-01+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | $10.95 | +73.6K | 22.5K | New | +$805.9K |
| DM | 2024-09-04 | 2024-09-01+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $26.74 | -1,738 | 21.7K | -7% | -$46.5K |
| DM | 2024-09-04 | 2024-09-03 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | S - Sale+OE | $26.12 | -68.5K | 22.9K | -75% | -$1.79M |
| D | 2024-04-08 | 2024-04-08 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +2,477 | 17.6K | +16% | — |
| D | 2024-04-08 | 2024-04-08 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $17.90 | -1,353 | 16.3K | -8% | -$24.2K |
| D | 2024-04-03 | 2024-04-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +1,612 | 16.0K | +11% | — |
| D | 2024-04-03 | 2024-04-01 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $19.70 | -880 | 15.2K | -5% | -$17.3K |
| DM | 2023-09-06 | 2023-09-01+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +3,471 | 15.0K | +30% | — |
| DM | 2023-09-06 | 2023-09-01+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $17.76 | -1,896 | 14.4K | -12% | -$33.7K |
| D | 2023-09-06 | 2023-07-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | A - Grant | $12.35 | +292 | 12.8K | +2% | +$3,606 |
| D | 2023-04-11 | 2023-04-10 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $10.71 | -1,353 | 12.6K | -10% | -$14.5K |
| D | 2023-04-11 | 2023-04-10 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +2,477 | 13.9K | +22% | — |
| DM | 2023-03-20 | 2023-03-16+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +3,131 | 11.0K | +40% | — |
| DM | 2023-03-20 | 2023-03-16+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $11.23 | -1,710 | 11.4K | -13% | -$19.2K |
| D | 2023-03-20 | 2023-01-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | A - Grant | $9.56 | +1,844 | 10.0K | +23% | +$17.6K |
| D | 2022-09-06 | 2022-07-15 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | A - Grant | $9.56 | +360 | 7,732 | +5% | +$3,442 |
| D | 2022-09-06 | 2022-09-02 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +995 | 8,727 | +13% | — |
| D | 2022-09-06 | 2022-09-02 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $11.44 | -563 | 8,164 | -6% | -$6,441 |
| D | 2022-03-23 | 2022-03-21 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | M - OptEx | — | +2,270 | 8,612 | +36% | — |
| D | 2022-03-23 | 2022-03-21 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief COMMERCIAL Off | F - Tax | $10.98 | -1,240 | 7,372 | -14% | -$13.6K |
| D | 2022-03-18 | 2022-03-16 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief Commercial Off | F - Tax | $10.13 | -544 | 6,342 | -8% | -$5,511 |
| D | 2022-03-18 | 2022-03-16 | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief Commercial Off | M - OptEx | — | +995 | 6,886 | +17% | — |
| DM | 2022-03-18 | 2021-07-15+ | KNSA | Kiniksa Pharmaceuticals International, plc | Moat Ross | Chief Commercial Off | A - Grant | $10.34 | +2,509 | 5,891 | +74% | +$26.0K |
Purchase Sale Sale after option exercise All abbreviations